General MedicationsTRANSDERMALStandard
RIVASTIGMINE
RIVASTIGMINE
Standard Dose
13.3MG/24HR
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview RIVASTIGMINE is listed in Drugs@FDA under application 215445 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient RIVASTIGMINE Form and strength FILM, EXTENDED RELEASE;TRANSDERMAL - 13.3MG/24HR Sponsor YICHANG HUMANWELL Submission history Latest submission status date: 2025-09-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview RIVASTIGMINE is listed in Drugs@FDA under application 215445 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient RIVASTIGMINE Form and strength FILM, EXTENDED RELEASE;TRANSDERMAL - 13.3MG/24HR Sponsor YICHANG HUMANWELL Submission history Latest submission status date: 2025-09-23 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.